The FDA has granted a priority review to a new drug application (NDA) for lirafugratinib, a highly selective oral FGFR2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results